View Item 

Show simple item record

GH Receptor Antagonist: Mechanism of Action and Clinical Utility

dc.contributor.authorSurya, Sowmya K.en_US
dc.contributor.authorBarkan, Ariel L.en_US
dc.date.accessioned2006-09-11T19:29:33Z
dc.date.available2006-09-11T19:29:33Z
dc.date.issued2005-01en_US
dc.identifier.citationSurya, Sowmya K.; Barkan, Ariel L.; (2005). "GH Receptor Antagonist: Mechanism of Action and Clinical Utility." Reviews in Endocrine and Metabolic Disorders 6(1): 5-13. <http://hdl.handle.net/2027.42/47874>en_US
dc.identifier.issn1389-9155en_US
dc.identifier.issn1573-2606en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/47874
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15711909&dopt=citationen_US
dc.description.abstractThis review focuses on the development of GH receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. A brief overview of acromegaly, its diagnosis and existing medical, surgical and radiotherapy options of treatment is necessary to justify the addition of yet another therapeutic modality to the already vast therapeutic armamentarium.en_US
dc.format.extent156427 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Media, Inc.en_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherInternal Medicineen_US
dc.subject.otherDiabetesen_US
dc.subject.otherAcromegalyen_US
dc.subject.otherGH Receptor Antagonistsen_US
dc.subject.otherPegvisomanten_US
dc.titleGH Receptor Antagonist: Mechanism of Action and Clinical Utilityen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Endocrinology, , University of Michigan Hospitals, , , Box 0354, , 3920 Taubman Center, 1500 E. Medical Center Drive, , Ann Arbor, , MI, , 48109, , USA,en_US
dc.contributor.affiliationumDivision of Endocrinology, , University of Michigan Hospitals, , , Box 0354, , 3920 Taubman Center, 1500 E. Medical Center Drive, , Ann Arbor, , MI, , 48109, , USA,en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid15711909en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/47874/1/11154_2005_Article_5219.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s11154-005-5219-xen_US
dc.identifier.sourceReviews in Endocrine and Metabolic Disordersen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
11154_2005_Article_5219.pdf
Size:
152.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.